Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

IGFBP-3 Mouse/ Rat ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Insulin-Like Growth Factor Binding Protein-3
  • Species:Mouse, Rat
Please select your region to see available products and prices.
Cat. No. Size Price


RMEE031R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.078–5 ng/ml

Limit of Detection

0.018 ng/ml

Summary

Features

  • Quantitative determination of mouse/rat IGFBP-3 without sample pretreatment
  • Inter-Assay variation of 8.4% and Intra-Assay variation of 4.6%
  • Analytical sensitivity of 0.018 ng/ml (18 pg/ml; 1,8 pg/well)

Research topic

Animal studies, Growth hormone and factor-related products

Summary

Growth Hormone, Insulin-like Growth Factors and their binding proteins build up an endocrine system regulating not only longitudinal growth in humans but also influencing a broad variety of other physiological and pathophysiological processes like energy metabolism or tumor growth. Most effects of Growth Hormone (GH) are exerted by Insulin-like Growth Factors (IGF) mainly produced by the liver but also locally by specific tissues. The effects of IGF are also regulated. Specific binding proteins (IGFBP 1-7) regulate bioavailability of IGF. After proteolytic cleavage of the binding proteins IGF is set free and able to bind to its receptor. The autophosphorylation of this thyrosine kinase receptor activates intra cellular signalling cascades. Some of these IGFBPs not only regulate the availability of IGF but also exert IGF-independent effects on cell physiology.
IGFBP-3 is the most abundant IGFBP in circulation and therefore of special relevance in regulation of IGF effects. This is reflected by the indicative value of serum IGFBP-3 concentration in diagnostics of growth disturbances. IGFBP-3 has also been shown to be able to induce apoptosis, promote tumor growth and inhibit cellular migration and metastasis dependent on tissue and tumor stage.

References to Product

References

  • Nicolas-Frances V, Arnauld S, Kaminski J, Ver Loren van Themaat E, Clemencet MC, Chamouton J, Athias A, Grober J, Gresti J, Degrace P, Lagrost L, Latruffe N, Mandard S. Disturbances in cholesterol, bile acid and glucose metabolism in peroxisomal 3-ketoacylCoA thiolase B deficient mice fed diets containing high or low fat contents. Biochimie. 2014 Mar;98:86-101
References to Summary

References to IGFBP-3

  • Ballard J, Baxter R, Binoux M, Clemmons D, Drop S, Hall K, Hintz R, Rechler M, Rutanen E, Schwander J. On the nomenclature of the IGF binding proteins. Acta Endocrinol (Copenh). 1989 Nov;121 (5):751-2
  • Baxter RC. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988 Aug;67 (2):265-72
  • Baxter RC, Martin JL. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 1986 Dec;78 (6):1504-12
  • Baxter RC, Martin JL. Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci U S A. 1989 Sep;86 (18):6898-902
  • Blum WF, Ranke MB. Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res. 1990;33 Suppl 4:31-7
  • Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990 May;70 (5):1292-8
  • Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002 Dec;23 (6):824-54
  • Holman SR, Baxter RC. Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation. Growth Regul. 1996 Mar;6 (1):42-7
  • Lee PD, Hintz RL, Sperry JB, Baxter RC, Powell DR. IGF binding proteins in growth-retarded children with chronic renal failure. Pediatr Res. 1989 Oct;26 (4):308-15
  • Schneider MR, Lahm H, Wu M, Hoeflich A, Wolf E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J. 2000 Apr;14 (5):629-40
  • Silha JV, Murphy LJ. Insulin-like growth factor binding proteins in development. Adv Exp Med Biol. 2005;567:55-89
  • Silha JV, Murphy LJ. Insights from insulin-like growth factor binding protein transgenic mice. Endocrinology. 2002 Oct;143 (10):3711-4
  • Wilson EM, Oh Y, Rosenfeld RG. Generation and characterization of an IGFBP-7 antibody: identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab. 1997 Apr;82 (4):1301-3
  • Yakar S, Sun H, Zhao H, Pennisi P, Toyoshima Y, Setser J, Stannard B, Scavo L, Leroith D. Metabolic effects of IGF-I deficiency: lessons from mouse models. Pediatr Endocrinol Rev. 2005 Sep;3 (1):11-9
Related Products Documents